The recent availability of selective inhibitors of the JAK/STAT signaling pathway, which have so far been approved for the treatment of inflammatory rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, has prompted a push to study their efficacy in GCA as well. The gene discussed is SOAT1; the disease is ankylosing spondylitis.